FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celJohnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), Share XFDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celhttps://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
